Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis

Sofia Perea, Manuel Hidalgo, Alberto Arcediano, Maria Jose Ramos, Carlos Gomez, Javier Hornedo, Carlos Lumbreras, Dolores Folgueira, Hernan Cortes-Funes, Antonio Rodriguez-Noriega

Research output: Contribution to journalArticle

Abstract

This study evaluated the susceptibility of Escherichia coli to quinolones in 72 stool samples collected from 31 patients with solid tumours who had undergone high dose chemotherapy (HDC) and peripheral blood stem-cell (PBSC) rescue with ciprofloxacin prophylaxis. Samples were obtained at admission, after completing prophylaxis and three months later. All E. coli strains isolated from baseline samples were susceptible to quinolones. Fluoroquinolone-resistant E. coli strains were isolated in 10 (32%) patients in the second sample. In eight of these patients isolates were susceptible 3 months later. No patient developed infection due to fluorquinolone-resistant E. coli. No differences were observed in outcome between patients with susceptible and resistant flora.

Original languageEnglish (US)
Pages (from-to)117-120
Number of pages4
JournalThe Journal of antimicrobial chemotherapy
Volume44
Issue number1
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Fluoroquinolones
Ciprofloxacin
Escherichia coli
Drug Therapy
Incidence
Quinolones
Neoplasms
Infection

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology

Cite this

Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis. / Perea, Sofia; Hidalgo, Manuel; Arcediano, Alberto; Ramos, Maria Jose; Gomez, Carlos; Hornedo, Javier; Lumbreras, Carlos; Folgueira, Dolores; Cortes-Funes, Hernan; Rodriguez-Noriega, Antonio.

In: The Journal of antimicrobial chemotherapy, Vol. 44, No. 1, 1999, p. 117-120.

Research output: Contribution to journalArticle

Perea, S, Hidalgo, M, Arcediano, A, Ramos, MJ, Gomez, C, Hornedo, J, Lumbreras, C, Folgueira, D, Cortes-Funes, H & Rodriguez-Noriega, A 1999, 'Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis', The Journal of antimicrobial chemotherapy, vol. 44, no. 1, pp. 117-120. https://doi.org/10.1093/jac/44.1.117
Perea, Sofia ; Hidalgo, Manuel ; Arcediano, Alberto ; Ramos, Maria Jose ; Gomez, Carlos ; Hornedo, Javier ; Lumbreras, Carlos ; Folgueira, Dolores ; Cortes-Funes, Hernan ; Rodriguez-Noriega, Antonio. / Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis. In: The Journal of antimicrobial chemotherapy. 1999 ; Vol. 44, No. 1. pp. 117-120.
@article{69b81e4fc6104ea3ae92cc635896101a,
title = "Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis",
abstract = "This study evaluated the susceptibility of Escherichia coli to quinolones in 72 stool samples collected from 31 patients with solid tumours who had undergone high dose chemotherapy (HDC) and peripheral blood stem-cell (PBSC) rescue with ciprofloxacin prophylaxis. Samples were obtained at admission, after completing prophylaxis and three months later. All E. coli strains isolated from baseline samples were susceptible to quinolones. Fluoroquinolone-resistant E. coli strains were isolated in 10 (32{\%}) patients in the second sample. In eight of these patients isolates were susceptible 3 months later. No patient developed infection due to fluorquinolone-resistant E. coli. No differences were observed in outcome between patients with susceptible and resistant flora.",
author = "Sofia Perea and Manuel Hidalgo and Alberto Arcediano and Ramos, {Maria Jose} and Carlos Gomez and Javier Hornedo and Carlos Lumbreras and Dolores Folgueira and Hernan Cortes-Funes and Antonio Rodriguez-Noriega",
year = "1999",
doi = "10.1093/jac/44.1.117",
language = "English (US)",
volume = "44",
pages = "117--120",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis

AU - Perea, Sofia

AU - Hidalgo, Manuel

AU - Arcediano, Alberto

AU - Ramos, Maria Jose

AU - Gomez, Carlos

AU - Hornedo, Javier

AU - Lumbreras, Carlos

AU - Folgueira, Dolores

AU - Cortes-Funes, Hernan

AU - Rodriguez-Noriega, Antonio

PY - 1999

Y1 - 1999

N2 - This study evaluated the susceptibility of Escherichia coli to quinolones in 72 stool samples collected from 31 patients with solid tumours who had undergone high dose chemotherapy (HDC) and peripheral blood stem-cell (PBSC) rescue with ciprofloxacin prophylaxis. Samples were obtained at admission, after completing prophylaxis and three months later. All E. coli strains isolated from baseline samples were susceptible to quinolones. Fluoroquinolone-resistant E. coli strains were isolated in 10 (32%) patients in the second sample. In eight of these patients isolates were susceptible 3 months later. No patient developed infection due to fluorquinolone-resistant E. coli. No differences were observed in outcome between patients with susceptible and resistant flora.

AB - This study evaluated the susceptibility of Escherichia coli to quinolones in 72 stool samples collected from 31 patients with solid tumours who had undergone high dose chemotherapy (HDC) and peripheral blood stem-cell (PBSC) rescue with ciprofloxacin prophylaxis. Samples were obtained at admission, after completing prophylaxis and three months later. All E. coli strains isolated from baseline samples were susceptible to quinolones. Fluoroquinolone-resistant E. coli strains were isolated in 10 (32%) patients in the second sample. In eight of these patients isolates were susceptible 3 months later. No patient developed infection due to fluorquinolone-resistant E. coli. No differences were observed in outcome between patients with susceptible and resistant flora.

UR - http://www.scopus.com/inward/record.url?scp=0032837575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032837575&partnerID=8YFLogxK

U2 - 10.1093/jac/44.1.117

DO - 10.1093/jac/44.1.117

M3 - Article

VL - 44

SP - 117

EP - 120

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 1

ER -